1. Home
  2. PK vs ZLAB Comparison

PK vs ZLAB Comparison

Compare PK & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$11.04

Market Cap

2.1B

Sector

Real Estate

ML Signal

HOLD

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

HOLD

Current Price

$19.58

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
ZLAB
Founded
1946
2013
Country
United States
China
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.4B
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
PK
ZLAB
Price
$11.04
$19.58
Analyst Decision
Hold
Strong Buy
Analyst Count
9
5
Target Price
$11.22
$49.60
AVG Volume (30 Days)
4.2M
626.3K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
8.82%
N/A
EPS Growth
N/A
38.46
EPS
0.05
N/A
Revenue
$2,791,000,000.00
$460,156,000.00
Revenue This Year
$2.40
$9.75
Revenue Next Year
$2.76
$26.03
P/E Ratio
$226.30
N/A
Revenue Growth
2.35
15.33
52 Week Low
$9.84
$15.96
52 Week High
$12.39
$44.34

Technical Indicators

Market Signals
Indicator
PK
ZLAB
Relative Strength Index (RSI) 47.06 42.28
Support Level $10.85 $19.51
Resistance Level $11.79 $19.64
Average True Range (ATR) 0.34 0.99
MACD -0.03 -0.47
Stochastic Oscillator 12.70 22.01

Price Performance

Historical Comparison
PK
ZLAB

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

Share on Social Networks: